We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth [Yahoo! Finance]
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results